Attached files
| file | filename |
|---|---|
| EX-4.1 - EXHIBIT 4.1 - Ocuphire Pharma, Inc. | ex4_1.htm |
| EX-1.1 - EXHIBIT 1.1 - Ocuphire Pharma, Inc. | ex1_1.htm |
| 8-K - 8-K - Ocuphire Pharma, Inc. | form8k.htm |
Exhibit 5.1
 |
Hogan Lovells US LLP
Harbor East
100 International Drive
Suite 2000
Baltimore, MD 21202
T +1 410 659 2700
F +1 410 659 2701
www.hoganlovells.com
|
January 25, 2019
Board of Directors
Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville, MD 20850
Ladies and Gentlemen:
We are acting as counsel to Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the proposed public offering of: (i) 10,750,000 shares of common stock, par value $0.0001 per share (“Common Stock”) of the Company (the “Shares”); (ii) warrants to purchase
up to 10,750,000 shares of Common Stock in the form filed by the Company as Exhibit 4.1 to its Current Report on Form 8-K on the date hereof (the “Warrants”);
and (iii) 10,750,000 shares of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”), pursuant to its registration statement on Form
S‑3, as amended (file no. 333-218285) (the “Registration Statement”), filed with the Securities and Exchange Commission under the Securities Act of 1933, as
amended (the “Act”), the accompanying prospectus dated July 11, 2017 (the “Base
Prospectus”) that forms a part thereof and the Prospectus Supplement dated January 23, 2019 (the “Prospectus Supplement” and together with the Base
Prospectus, the “Prospectus”). The Shares and the Warrants are to be sold by the Company pursuant to the Underwriting Agreement, dated January 23, 2019,
among the Company and the underwriters named therein (the “Underwriting Agreement”). This opinion letter is furnished to you at your request to enable you to
fulfill the requirements of Item 601(b)(5) of Regulation S‑K, 17 C.F.R. § 229.601(b)(5), in connection with the Registration Statement.
For purposes of this opinion letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate basis on
which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents
submitted to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to
all matters of fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and all statements
herein are made, in the context of the foregoing.
Hogan Lovells US LLP is a limited liability partnership registered in the District of Columbia. “Hogan Lovells” is an international legal practice that includes
Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: Alicante Amsterdam Baltimore Beijing Birmingham Boston Brussels Colorado Springs Denver Dubai Dusseldorf Frankfurt Hamburg Hanoi
Ho Chi Minh City Hong Kong Houston Johannesburg London Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Moscow Munich New York Northern Virginia Paris Perth Philadelphia
Rio de Janeiro Rome San Francisco São Paulo Shanghai Silicon Valley Singapore Sydney Tokyo Warsaw Washington DC Associated offices: Budapest Jakarta Shanghai FTZ Ulaanbaatar Zagreb. Business Service Centers:
Johannesburg Louisville. For more information see www.hoganlovells.com
|
Board of Directors
Rexahn Pharmaceuticals, Inc.
|
- 2 -
|
January 25, 2019
|
This opinion letter is based as to matters of law solely on the applicable provisions of the following, as currently in effect: (i) the Delaware
General Corporation Law, as amended, and (ii) as to the opinion given in paragraph (b), the laws of the State of New York (but not including any laws, statutes, ordinances, administrative decisions, rules or regulations of any political
subdivision below the state level). We express no opinion herein as to any other statutes, rules or regulations (and in particular, we express no opinion as to any effect
that such other statutes, rules or regulations may have on the opinions expressed herein).
Based upon, subject to and limited by the foregoing, we are of the opinion that:
| (a) |
Following (i) issuance of the Shares pursuant to the terms of the Underwriting Agreement, and (ii) receipt by the Company of the consideration for the Shares specified
in the resolutions of the Pricing Committee of the Board of Directors, the Shares will be validly issued, fully paid, and nonassessable.
|
| (b) |
Following (i) execution and delivery by the Company of the Warrants pursuant to the terms of the Underwriting Agreement, and (ii) receipt by the Company of the
consideration for the Warrants specified in the resolutions of the Pricing Committee of the Board of Directors, the Warrants will constitute valid and binding obligations of the Company.
|
| (c) |
Following (i) execution and delivery by the Company of the Warrants pursuant to the terms of the Underwriting Agreement, (ii) receipt by the Company of the
consideration for the Warrants specified in the resolutions of the Pricing Committee of the Board of Directors, and (iii) exercise of the Warrants pursuant to their terms, receipt by the Company of the exercise price for the Warrant
Shares as specified in the Warrants and issuance of the Warrant Shares thereunder, the Warrant Shares will be validly issued, fully paid, and nonassessable.
|
The opinion expressed in paragraph (b) above with respect to the valid and binding nature of obligations may be limited by bankruptcy, insolvency,
reorganization, receivership, moratorium or other laws affecting creditors’ rights (including, without limitation, the effect of statutory and other law regarding fraudulent conveyances, fraudulent transfers and preferential transfers) and by
the exercise of judicial discretion and the application of principles of equity, good faith, fair dealing, reasonableness, conscionability and materiality (regardless of whether the Warrants are considered in a proceeding in equity or at law).
This opinion letter has been prepared for use in connection with the Registration Statement. We assume no obligation to advise of any changes in the
foregoing subsequent to the date hereof.
We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Company’s Current Report on Form 8-K to be filed with the Securities and
Exchange Commission on the date hereof and to the reference to this firm under the caption “Legal Matters” in the Prospectus constituting a part of the Registration Statement. In giving this consent, we do not thereby admit that we are an
“expert” within the meaning of the Act.
Very truly yours,
/s/ HOGAN LOVELLS US LLP
HOGAN LOVELLS US LLP